Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 6:19 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 544 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Resected Stage Clear all
Withdrawn Phase 1Phase 2 Interventional

Near-Infrared Image Guided Surgical Resection With Indocyanine Green in Treating Patients With Head and Neck Cancer

NCT03745690
View directory record Official record
Conditions
Head and Neck Carcinoma
Interventions
Image-Guided Surgery, Indocyanine Green Drug
Procedure · Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 17, 2022 · Synced Oct 24, 2026, 6:19 AM EDT
Completed Phase 3 Interventional Results available

Stereotactic Radiosurgery or Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases That Have Been Removed By Surgery

NCT01372774
View directory record Official record
Conditions
Cognitive/Functional Effects, Metastatic Cancer, Neurotoxicity, Radiation Toxicity, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
stereotactic radiosurgery, whole-brain radiation therapy
Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
37
States / cities
Burlingame, California • Los Angeles, California • Newark, Delaware + 30 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2022 · Synced Oct 24, 2026, 6:19 AM EDT
Active, not recruiting Phase 3 Interventional

Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery

NCT03180268
View directory record Official record
Conditions
Grade 2 Meningioma, Intracranial Meningioma
Interventions
Biospecimen Collection, Clinical Observation, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Proton Beam Radiation Therapy, Quality-of-Life Assessment
Procedure · Other · Radiation
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2032
U.S. locations
198
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 162 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 24, 2026, 6:19 AM EDT
Completed Not applicable Interventional Results available

Two Stage Study Of Single Dose PEGPH20 And Cetuximab In Patients With Pancreatic Adenocarcinoma Prior To Surgical Resection

NCT02241187
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
PEGPH20, Cetuximab, DW & DCE-MRI, blood draws
Drug · Device · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 27, 2017 · Synced Oct 24, 2026, 6:19 AM EDT
Completed Phase 1 Interventional

Combination Chemotherapy Following Surgery in Treating Patients With Advanced Bladder Cancer

NCT00003133
View directory record Official record
Conditions
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Interventions
filgrastim, cisplatin, doxorubicin hydrochloride, gemcitabine hydrochloride, paclitaxel
Biological · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2003
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 28, 2013 · Synced Oct 24, 2026, 6:19 AM EDT
Not yet recruiting Early Phase 1 Interventional

A Study of NST-628 in Recurrent Grade 4 Glioma

NCT07784985
View directory record Official record
Conditions
Glioma, Recurrent High Grade, Grade 4 Malignant Glioma
Interventions
NST-628
Drug
Lead sponsor
Nader Sanai
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 24, 2026, 6:19 AM EDT
Completed Phase 2 Interventional

Vaccine Therapy With or Without Interleukin-12 in Treating Patients With Stage III or Stage IV Melanoma

NCT00003339
View directory record Official record
Conditions
Intraocular Melanoma, Melanoma (Skin)
Interventions
gp100 antigen, incomplete Freund's adjuvant, recombinant interleukin-12, tyrosinase peptide
Biological
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2004
U.S. locations
2
States / cities
Duarte, California • Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 22, 2014 · Synced Oct 24, 2026, 6:19 AM EDT
Terminated Phase 2 Interventional

Continuation Booster Trial After a Vaccine Combining Tyrosinase/GP100/MART-1 Peptides Emulsified With Montanide ISA 51 With or Without GM-CSF for Patients With Melanoma

NCT00184067
View directory record Official record
Conditions
Melanoma
Interventions
Montanide ISA 51
Biological
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 21, 2014 · Synced Oct 24, 2026, 6:19 AM EDT
Not listed Phase 2 Interventional

Safety and Efficacy Study of TVGV-1 Vaccine to Treat HPV Induced Cervical HSIL

NCT02576561
View directory record Official record
Conditions
Human Papillomavirus, High-Grade Squamous Intraepithelial Lesions
Interventions
TVGV-1, GPI-0100, Placebo
Biological
Lead sponsor
THEVAX Genetics Vaccine
Industry
Eligibility
18 Years to 55 Years · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
11
States / cities
Tucson, Arizona • Lakewood, Colorado • Port Orange, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2017 · Synced Oct 24, 2026, 6:19 AM EDT
Completed Phase 2 Interventional Results available

Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma

NCT00084656
View directory record Official record
Conditions
Intraocular Melanoma, Melanoma (Skin)
Interventions
ipilimumab, Tyrosinase/gp100/MART-1 Peptides
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 120 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 14, 2022 · Synced Oct 24, 2026, 6:19 AM EDT
Completed Phase 1Phase 2 Interventional

Vaccine Treatment for Surgically Resected Pancreatic Cancer

NCT00255827
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
HyperAcute-Pancreatic Cancer Vaccine
Biological
Lead sponsor
NewLink Genetics Corporation
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 28, 2020 · Synced Oct 24, 2026, 6:19 AM EDT
Terminated Not applicable Interventional Results available

Thoracoscopic Lung Cancer Staging With the Use of Intraoperative Ultrasound

NCT02218242
View directory record Official record
Conditions
Lung Cancer
Interventions
Intraoperative ultrasound
Device
Lead sponsor
Joel Thompson, PhD
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Nov 7, 2018 · Synced Oct 24, 2026, 6:19 AM EDT
Recruiting Phase 1Phase 2 Interventional

PBGENE-DMD Phase 1/2a Safety and Preliminary Efficacy Study in Duchenne Muscular Dystrophy (FUNCTION-DMD)

NCT07429240
View directory record Official record
Conditions
Duchenne Muscular Dystrophy With Mutations Amenable to PBGENE-DMD
Interventions
PBGENE-DMD (IV)
Biological
Lead sponsor
Precision BioSciences, Inc.
Industry
Eligibility
2 Years to 7 Years · Male only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Little Rock, Arkansas • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 24, 2026, 6:19 AM EDT
Completed Phase 1 Interventional

IL13-PE38QQR Infusion After Tumor Resection, Followed by Radiation Therapy With or Without Temozolomide in Patients With Newly Diagnosed Malignant Glioma

NCT00089427
View directory record Official record
Conditions
Glioblastoma Multiforme, Anaplastic Astrocytoma, Oligoastrocytoma
Interventions
IL13-PE38QQR, Surgery for placement, Radiation therapy, Temozolomide with radiation therapy
Drug · Procedure
Lead sponsor
INSYS Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
6
States / cities
San Francisco, California • Charlotte, North Carolina • Durham, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 4, 2011 · Synced Oct 24, 2026, 6:19 AM EDT
Completed Phase 2 Interventional Results available

Liver Resection and Floxuridine Plus Fluorouracil and Leucovorin in Treating Patients With Liver Metastases From Colorectal Cancer

NCT00002842
View directory record Official record
Conditions
Colorectal Cancer, Metastatic Cancer
Interventions
floxuridine, fluorouracil, leucovorin calcium, adjuvant therapy, conventional surgery
Drug · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2014
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Apr 11, 2017 · Synced Oct 24, 2026, 6:19 AM EDT
Active, not recruiting Phase 2 Interventional

Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery

NCT05111574
View directory record Official record
Conditions
Anal Melanoma, Bladder Melanoma, Cervical Melanoma, Esophageal Melanoma, Gallbladder Melanoma, Head and Neck Mucosal Melanoma, Mucosal Melanoma, Nasopharyngeal Mucosal Melanoma, Oral Cavity Mucosal Melanoma, Penile Mucosal Melanoma, Rectal Melanoma, Recurrent Mucosal Melanoma, Sinonasal Mucosal Melanoma, Urethral Melanoma, Urinary System Mucosal Melanoma, Vaginal Melanoma, Vulvar Melanoma
Interventions
Biospecimen Collection, Bone Scan, Cabozantinib S-malate, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Nivolumab, Placebo Administration, Positron Emission Tomography
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
142
States / cities
Auburn, California • Berkeley, California • Fremont, California + 116 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 24, 2026, 6:19 AM EDT
Completed Phase 2 Interventional

Chemotherapy, Amifostine, and Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer

NCT00003089
View directory record Official record
Conditions
Drug/Agent Toxicity by Tissue/Organ, Lung Cancer
Interventions
amifostine trihydrate, carboplatin, paclitaxel, radiation therapy
Drug · Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2004
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 10, 2013 · Synced Oct 24, 2026, 6:19 AM EDT
Completed Phase 3 Interventional Results available

Study Of Adjuvant Lapatinib In High-Risk Head And Neck Cancer Subjects After Surgery

NCT00424255
View directory record Official record
Conditions
Neoplasms, Head and Neck
Interventions
Lapatinib, Chemoradiation, Placebo
Drug · Radiation · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 70 Years
Enrollment
688 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
5
States / cities
Springfield, Illinois • St Louis, Missouri • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2014 · Synced Oct 24, 2026, 6:19 AM EDT
Terminated Phase 2 Interventional Results available

Neo-Adjuvant FOLFOX for Rectal Carcinoma

NCT00832299
View directory record Official record
Conditions
Rectal Neoplasms
Interventions
FOLFOX, total mesorectal excision (TME)
Drug · Procedure
Lead sponsor
Beth Israel Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 1, 2018 · Synced Oct 24, 2026, 6:19 AM EDT
Terminated Phase 3 Interventional Results available

Surgery With or Without Internal Radiation Therapy Compared With Stereotactic Body Radiation Therapy in Treating Patients With High-Risk Stage I Non-Small Cell Lung Cancer

NCT01336894
View directory record Official record
Conditions
Lung Cancer
Interventions
therapeutic conventional surgery, iodine I 125, stereotactic body radiation therapy
Procedure · Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
49
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 41 more
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 24, 2026, 6:19 AM EDT
Active, not recruiting Phase 2 Interventional

Intravesical Gem/Doce in Patients With NMIBC

NCT05644041
View directory record Official record
Conditions
Urinary Bladder Cancer
Interventions
gemcitabine + docetaxel
Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 24, 2026, 6:19 AM EDT
Completed Phase 2 Interventional Results available

Ph II Adjuvant Carboplatin/Docetaxel in Curatively Resected Stage I-IIIA NSCLC

NCT00280735
View directory record Official record
Conditions
Lung Cancer
Interventions
carboplatin, docetaxel
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 11, 2017 · Synced Oct 24, 2026, 6:19 AM EDT
Not listed Not applicable Interventional

Cryoablation of Small Breast Tumors in Early Stage Breast Cancer

NCT01992250
View directory record Official record
Conditions
Breast Cancer
Interventions
Visica 2 Treatment System
Device
Lead sponsor
Sanarus Technologies, Inc.
Industry
Eligibility
50 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
12
States / cities
Scottsdale, Arizona • Beverly Hills, California • Duarte, California + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2018 · Synced Oct 24, 2026, 6:19 AM EDT
Completed No phase listed Observational

Studying Fibroblast Activity in Patients With Localized Pancreatic Cancer Undergoing Surgery

NCT00900016
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
protein expression analysis, western blotting, immunohistochemistry staining method, immunologic technique, laboratory biomarker analysis
Genetic · Other
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
Not listed
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 11, 2017 · Synced Oct 24, 2026, 6:19 AM EDT